Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B
Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (1) · 50-61
DOI: 10.1111/apt.70637 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, published online on 2026-03-23. Written by Shuaibing Ying and 14 co-authors. Institution: Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, State Key Laboratory for Diagnosis and Treatment of Infectious Disease…. Major MEDLINE topics: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Hepatitis B Surface Antigens. Cited 3 times so far (Crossref); 32 references. Funded by: Clinical Collaboration Project on Integrated Traditional Chinese and Western Medicine for Major and Difficult Diseases, Basic Public Welfare Research Program of Zhejiang Province, National Natural Science Foundation of China.
Abstract (original language)
Background
Prediction of hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) after hepatitis B surface antigen (HBsAg) seroclearance is important for optimizing surveillance strategies.
Aim
This study aimed to identify independent risk factors of HCC after HBsAg seroclearance and to develop and validate a risk prediction model.
Methods
A total of 6536 CHB patients who achieved HBsAg seroclearance between January 2006 and June 2025 were retrospectively screened, with 3852 patients meeting the criteria for final analysis. A predictive model was developed via multivariate Cox proportional hazards regression analysis, with discrimination assessed using Harrell's C‐index and time‐dependent receiver operating characteristic curve area under the curve (AUC). Internal validation of the model was conducted through bootstrap resampling analysis.
Results
During 21,711 person‐years of follow‐up, 128 patients (3.3%) developed HCC (incidence rate: 0.59% per year). Multivariable analysis identified age, male sex, cirrhosis, antiviral therapy (AVT)‐induced seroclearance and lower levels of platelets and albumin as independent predictors of HCC. The six independent variables were used for constructing the novel prediction model. Harrell's C‐index of the model was 0.766. The novel model has a good predictive ability for HCC risk in the 3‐year (AUC = 0.785), 5‐year (AUC = 0.775) and 10‐year (AUC = 0.830) with similar discriminative performance observed in internal validation.
Conclusions
The independent risk factors of HCC occurrence are age ≥ 50 years, male, platelet count≤ 150 × 10 9 /L, albumin level ≤ 44 g/L, with cirrhosis at HBsAg seroclearance and AVT‐induced HBsAg seroclearance. Our six‐factor model enables risk stratification among patients achieving HBsAg seroclearance and may assist in informing surveillance strategies in clinical practice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Departme…
- Westlake University, School of Medicine, Hangzhou, China.
ORCID profiles: Shuaibing Ying
Funding
- Clinical Collaboration Project on Integrated Traditional Chinese and Western Medicine for Major and Difficult Diseases
- Basic Public Welfare Research Program of Zhejiang Province
- National Natural Science Foundation of China
- Zhejiang Provincial and Ministry Co-construction Plan
- International Cooperation and Exchange Programs of the National Natural Science Foundation of China
- National Key Research and Development Program of China
Cite
APA
Ying, S., Dai, J., Zhang, Q., Wang, Y., Yu, Y., Zhang, Z., Dong, S., Zhang, Y., Hu, H., Hong, Y., Liu, Y., Guo, Y., Yan, H., Qiu, Y., & Lou, Y. (2026). Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics, 64(1), 50-61. https://doi.org/10.1111/apt.70637
Vancouver
Ying S, Dai J, Zhang Q, Wang Y, Yu Y, Zhang Z, et al. Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. 2026;64(1):50-61. doi:10.1111/apt.70637
BibTeX
@article{Ying2026,
author = {Ying, Shuaibing and Dai, Jinyao and Zhang, Qiudan and Wang, Yujing and Yu, Yina and Zhang, Zhijuan and Dong, Shaohua and Zhang, Yichun and Hu, Haoyang and Hong, Yuqi and Liu, Yi and Guo, Yuqi and Yan, Haomin and Qiu, Yunqing and Lou, Yan},
title = {Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {1},
pages = {50--61},
doi = {10.1111/apt.70637}
}
EUVIMED